Abstracts tagged "Takayasu.s arteritis"

Abstract Number: 1689 • 2013 ACR/ARHP Annual Meeting
Antiplatelet Agents Decrease Ischemic Complications In Systemic Large Vessel Vasculitides: A Meta-Analysis
James Jeong¹ and Lillian J. Barra², ¹Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada, ²Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: Large Vessel Vasculitides (LVV) consist of Giant Cell Arteritis and Takayasu’s Arteritis, which are chronic systemic autoimmune diseases characterized by inflammation of large blood…
Abstract Number: 1679 • 2013 ACR/ARHP Annual Meeting
Clinical Implications Of Antiphospholipid Antibodies In Takayasu’s Arteritis
Natasha Jordan¹, Holy Bezanahary¹ and David P. D'Cruz², ¹Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, ²Louise Coote Lupus Unit, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom
Background/Purpose: Takayasu’s arteritis (TA) is a granulomatous inflammation of unknown origin involving the aorta and its major branches. Association and implication of antiphospholipid antibodies (aPL)…
Abstract Number: 2387 • 2012 ACR/ARHP Annual Meeting
Takayasu’s Arteritis: Features and Management of 216 Patients in China
Xia Liu¹, Tao Zhang², Xiaofeng Zhuang³, Kai Yuan¹, Xiaoming Shu¹ and Guochun Wang¹, ¹Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing, China, ²Department of Vascular Surgery, Chinese PLA General Hospital, Beijing, China, ³Department of Cardiology, FuWai Hospital and Cardiovascular Institute, Beijing, China
Background/Purpose: Takayasu’s arteritis (TA) is a rare vasculitis. Although it appears to be most common in Asia countries, research on Chinese TA patients with large…
Abstract Number: 2366 • 2012 ACR/ARHP Annual Meeting
Aortic and Coronary Calcifications in Takayasu Arteritis
Emire Seyahi¹, Ayca Ucgul², Serdal Ugurlu¹, Canan Akman³, Deniz Cebi Olgun³, Sebahattin Yurdakul¹ and Hasan Yazici¹, ¹Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey, ²Internal Medicine, University of Istanbul, Cerrahpasa Medical Faculty, Istanbul, Turkey, ³Radiology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey
Aortic and coronary calcifications in Takayasu arteritisBackground/Purpose: We had previously shown, similar to patients with systemic lupus erythematosus (SLE), patients with Takayasu arteritis (TAK) had…
Abstract Number: 2367 • 2012 ACR/ARHP Annual Meeting
Presence of Fibromyalgia and Fatigue Is Not Increased in Patients with Takayasu’s Arteritis
Fatma Alibaz-Oner¹, Meryem Can¹, Birkan Ilhan², Ozge Polat² and Haner Direskeneli¹, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Takayasu’s arteritis (TAK) is a large-vessel vasculitis of the aorta and its major branches. To our knowledge, no data is reported about the frequency…
Abstract Number: 2368 • 2012 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Takayasu’s Arteritis: 7 Patients Followed At a Single Italian Centre
Enrico Tombetti¹, Elena Baldissera², Stefano Franchini¹, Patrizia Aiello³, Francesca Motta¹, Barbara Gulgielmi¹ and Maria Grazia Sabbadini¹, ¹Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy, ²Vita-Salute San Raffaele University, Milano, Italy, ³Internal Medicine and Clinical Immunology, Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milano, Italy
Background/Purpose: Takayasu arteritis (TA) is a rare chronic-relapsing vasculitis involving primarily the aorta and its major branches.TA is associated with considerable morbidity and mortality. Therapy…
Abstract Number: 2377 • 2012 ACR/ARHP Annual Meeting
Impaired Endothelial Function in Patients with Takayasu’s Arteritis
Fatma Alibaz-Oner¹, Selen Yurdakul², Yelda Tayyareci³, Saide Aytekin⁴ and Haner Direskeneli¹, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Cardiology, Bilim University, Faculty of Medicine, Cardiology Department, Istanbul, Turkey, ³Cardiology, ISTANBUL FLORENCE NIGHTINGALE HOSPITAL, Istanbul, Turkey, ⁴Cardiology, Istanbul Florence Nightingale Hospital, Cardiology, Istanbul, Turkey
Background/Purpose: Takayasu’ s arteritis (TAK) is a chronic, inflammatory, large-vessel vasculitis. In the present study we aimed to evaluate vascular endothelial function in patients with…
Abstract Number: 2380 • 2012 ACR/ARHP Annual Meeting
High Frequency of Ferritin Autoantibodies in Takayasu Arteritis
Niklas T. Baerlecken¹, Katherina Große², Frank Moosig³, Wolfgang L. Gross⁴, Reinhold E. Schmidt¹ and Torsten Witte⁵, ¹Clinical Immunology and Rheumatology, Medical University Hannover, Hannover, Germany, ²Department of Immunology and Rheumatology, Student, Hannover, Germany, ³University of Luebeck, Stormarnzing 156, Bad Bramstedt, Germany, ⁴Dept of Clinical Rheumatology, Medical University at Lubeck, Lubeck, Germany, ⁵Hannover Medical School, Hanover, Germany
Background/Purpose: Takayasu arteritis (TA) may be difficult to diagnose since diagnostic biomarkers have not been established so far. In a previous study, we could show…
Abstract Number: 2363 • 2012 ACR/ARHP Annual Meeting
Assessment of Disease Activity in Large Vessel Vasculitis: Initial Results of an International Delphi Exercise
Sibel Z. Aydin¹, Haner Direskeneli², Eric L. Matteson³ and Peter A. Merkel⁴, ¹Unit of Rheumatology, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, ²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Assessment of disease activity in large vessel vasculitis (LVV) is challenging. The lack of specific, validated outcome measurements for both Takayasu’s (TAK) and giant…
Abstract Number: 296 • 2012 ACR/ARHP Annual Meeting
A Brazilian Multicenter Study of 71 Children and Adolescents with Takayasu’s Arteritis
Maria Teresa Terreri¹, Gleice Clemente², Clovis Silva³, Silvana Sacchetti⁴, Adriana M. Sallum⁵, Lucia M. A. Campos⁶, Maria Carolina Santos⁴, Flavio Sztajnbok⁷, Rozana Gasparello de Almeida⁸, Virginia P. Ferriani⁹, Blanca E. Bica¹⁰, Teresa Robazzi¹¹, Marcia Bandeira¹², Andre Cavalcanti¹³, Marise Lessa¹⁴, Sheila K. Feitosa de Oliveira¹⁵ and Maria Odete Hilario¹⁶, ¹Pediatrics, Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, ²Pediatrics, Universidade Federal de São Paulo/UNIFESP, São Paulo, Brazil, ³Pediatric Rheumatology, MD; PhD, São Paulo-SP, Brazil, ⁴Pediatrics, Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo-SP, Brazil, ⁶Pediatric Rheumatology, University of São Paulo Medical School, São Paulo, Brazil, ⁷PRINTO, Genoa, Italy, ⁸Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹Pediatrics, FMUSP-Ribeirao Preto, Ribeirao Preto, Brazil, ¹⁰International Investigator Consortium for MAS Diagnostic Criteria, Rio de Janeiro, Brazil, ¹¹Pediatrics, Universidade Federal da Bahia, Salvador, Brazil, ¹²Pediatrics, Hospital Infantil Pequeno Príncipe, Curitiba, Brazil, ¹³Universidade Federal de Pernambuco, Recife, Brazil, ¹⁴Pediatrics, Instituto de Pediatria e Puericultura Martagão Gesteira (IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil, ¹⁵Pediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁶Pediatrics, Universidade Federal de Sao Paulo / UNIFESP, Sao Paulo, Brazil
Background/Purpose: Takayasu’s arteritis is a chronic granulomatous disease that affects the vascular wall of the large arteries and can result in end organ damage. It…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].